i
Important informations
Instagram
Portal
Donate now

Our researchers

Aucun résultat

Ryuhjin Ahn

Ryuhjin Ahn, PhD

Molecular & Regenerative Medicine

Brain cancers, Cell signaling, Functional proteomics, Immunopeptidomics, Phosphoproteomics, Systems biology, Tumor immunology, Tumor-host interaction
  • Principal Investigator, Lady Davis Institute for Medical Research
  • Assistant Professor, Department of Anatomy and Cell Biology, McGill University

Contact details

(514) 340-8222 ext. 27378 (office), ext. 56515 (lab)
ryuhjin.ahn@mcgill.ca
@RyuhjinAhn

Snapshot

The Ahn Lab studies how cancer cells communicate with and reprogram their microenvironment. We combine mass spectrometry-based functional proteomics, systems biology, and in vivo models to understand tumor–host interactions directly in tissues and determine how they drive tumor progression, shape immune responses, and promote therapeutic resistance. We use these insights to identify new strategies for treating cancers such as glioblastoma.

Important Links :

See Ryuhjin Ahn's publications on PubMed

Major Research Activities

The specific research areas in the laboratory include:

  • Decoding tumor–host communication: Applying innovative functional proteomics approaches to define how signaling networks are co-regulated across tumor, immune, and other host cells within the tumor microenvironment, and leveraging these insights to identify new therapeutic strategies for cancer.
  • Tumor–immune interactions in glioblastoma: Investigating how glioblastoma reprograms macrophage and microglial signaling and immune function, with a focus on innate immune checkpoints and mechanisms that regulate anti-tumor immunity and therapeutic response.
  • Technology development for tumor–host biology: Developing new proteomic approaches to resolve signaling at cell-type and single-cell resolution and characterize molecular interactions in vivo, enabling the study of tumor–host communication with greater spatial, cellular, and molecular precision.

Recent Publications and References

  • Uncovering the signaling networks of disseminated glioblastoma cells in vivo with INSIGHT.

    Ahn R*, D Souza AD, Long L, Cui Y, Gantchev J, Baquer G, Burgenske D, Bakken KK, Ott LL, Carlson BL, Zhou G, Kohale IN, Whittaker CA, Temple H, Yaron-Barir TM, Wyckoff J, Burns TC, Vaubel RA, Flower CT, Huang W, Tuma A, Johnson JL, Agar NYR, Ursini-Siegel J, Sarkaria JN, White FM*. Nat Commun. 2026;17(1):9536. doi:10.1038/s41467-026-76587-0. PMID: 42702597. *Co-corresponding authors

  • Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses.

    Ling AL*, Gantchev J*, Prabhu MC*, Basu S*, Ahn R*, D Souza A*, Masud N, Ball A, Nikas O, Villa GR, Regan MS, Baquer G, Ayoub G, Whittaker CA, Abou-Mrad Z, Santos A, Couturier CP, Elharouni D, Vogelzang J, Yu KKH, Chen H, He Z, Jiang W, Lucas CH, Sax HE, Lang FF, Puduvalli VK, Tabar V, Brennan CW, Boire A, Holdhoff M, Bettegowda C, Cima M, Solomon IH, Yuan Y, Tak PP, Accelerating GBM Therapies TeamLab, Sharma P, White FM, Ligon KL, Agar NYR, Reardon DA, Oliveira G, Chiocca EA. Sci Transl Med. 2025;17(819):eadv2881. doi:10.1126/scitranslmed.adv2881. PMID: 41061048.   * equal contribution

  • Investigative needle core biopsies support multimodal deep-data generation in glioblastoma.

    Yu KKH*, Basu S, Baquer G*, Ahn R*, Gantchev J*, Jindal S*, Regan MS, Abou-Mrad Z, Prabhu MC, Williams MJ, D Souza AD, Malinowski SW, Hopland K, Elhanati Y, Stopka SA, Stortchevoi A, Couturier C, He Z, Sun J, Chen Y, Espejo AB, Chow KH, Yerrum S, Kao PL, Kerrigan BP, Norberg L, Nielsen D; GBM TeamLab; Puduvalli VK, Huse J, Beroukhim R, Kim BYS, Goswami S, Boire A, Frisken S, Cima MJ, Holdhoff M, Lucas CG, Bettegowda C, Levine SS, Bale TA, Brennan C, Reardon DA, Lang FF, Chiocca EA, Ligon KL, White FM, Sharma P, Tabar V, Agar NYR. Nat Commun. 2025;16(1):3957. doi:10.1038/s41467-025-58452-8. PMID: 40295505. * equal contribution

  • Antigen discovery for the development of cancer immunotherapy.

    Ahn R, Cui Y, White FM. Semin Immunol. 2023;66:101733. doi:10.1016/j.smim.2023.101733. PMID: 36841147.

  • Deciphering the immunopeptidome in vivo reveals new tumour antigens.

    Jaeger AM, Stopfer LE, Ahn R, Sanders EA, Sandel DA, Freed-Pastor WA, Rideout WM 3rd, Naranjo S, Fessenden T, Nguyen KB, Winter PS, Kohn RE, Westcott PMK, Schenkel JM, Shanahan SL, Shalek AK, Spranger S, White FM, Jacks T. Nature. 2022;607(7917):149–155. doi:10.1038/s41586-022-04839-2. PMID: 35705813.

LDI logo
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.